Lumeda is advancing a new therapy to improve treatment outcomes and extend survival of patients with lung cancer

✧ Learn about our therapeutic solution

Lumeda DigiLum™ - A new paradigm in photodynamic therapy

Breakthrough Innovation in PDT to spur its adoption and clinical utility

✧ Learn more about our platform

A BETTER IMMUNE ADJUVANT

Working in synergy with immune checkpoint inhibitors to improve response and extend benefits to more patients without toxicities or side effects

✧ Learn more about our combination therapy

TEAM

We are a multidisciplinary team of highly experienced professionals with decades of industry experience augmented with a distinguished group of scientific, clinical, and oncology drug development advisors.

Learn More >

PARTNERS

We work closely with institutional and photosensitizer drug partners and leverage the expertise of established firms in support of our clinical development plan, regulatory affairs, and growth of our intellectual property portfolio.

Learn More >

CLINICAL STUDIES

We have implemented a clinical plan that starts with two Phase I clinical studies currently open to evaluate safety of the DigiLum™ system applied intraoperatively in standard of care thoracic procedures.

Learn More >

Company
Team
Therapeutic Solution
Technology
Platform
Contact
News